| Cat. No. |
Product Name |
Effect
|
Purity |
Rare Diseases
|
| HY-100742A |
(R)-GNE-140 |
Inhibitor |
99.77% |
Unkown |
| HY-145331A |
ARG1-IN-1 hydrochloride |
Inhibitor |
90.0% |
Unkown |
| HY-103544 |
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P |
|
98.48% |
Unkown |
| HY-N14001 |
Naamidine J |
|
99.41% |
Unkown |
| HY-169859 |
EP4 receptor antagonist 7 |
Antagonist |
99.9% |
Unkown |
| HY-P1490 |
Bradykinin (2-9) |
Modulator |
97.15% |
Unkown |
| HY-RS00907 |
ARG1 Human Pre-designed siRNA Set A |
Pre-designed Set |
/ |
Unkown |
| HY-145331 |
ARG1-IN-1 |
Inhibitor |
/ |
Unkown |
| HY-161061 |
Arginase inhibitor 7 |
Inhibitor |
/ |
Unkown |
| HY-163426S |
AFFGHYLYEVAR-(Arg-13C6,15N4) |
|
/ |
Unkown |
| HY-182719 |
AZD0011 |
Inhibitor |
/ |
Unkown |
| HY-184203 |
SM-06-09 |
Inhibitor |
/ |
Unkown |
| HY-N11451 |
Lacto-N-fucopentaose III |
Activator |
96.54% |
Unkown |
| HY-P11405 |
[D-Arg1,D-Trp5,7,9,Leu11]-Substance P |
Antagonist |
/ |
Unkown |
| HY-P11882 |
SYN1436 |
Antagonist |
/ |
Unkown |
| HY-P3225 |
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P acetate |
Antagonist |
/ |
Unkown |
| HY-P3880 |
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P |
Antagonist |
/ |
Unkown |
| HY-P3881 |
(D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P |
Antagonist |
/ |
Unkown |
| HY-P6421S |
LGPLVEQG-Arg(13C6,15N4) TFA |
|
/ |
Unkown |
| HY-P6422S |
LAVYQAGA-Arg(13C6,15N4) TFA |
|
/ |
Unkown |
| HY-P6423S |
CLAVYQAGA-Arg(13C6,15N4) TFA |
|
/ |
Unkown |
| HY-P6424S |
LGADMEDVCG-Arg(13C6,15N4) TFA |
|
/ |
Unkown |
| HY-RS14543 |
TINAGL1 Human Pre-designed siRNA Set A |
Pre-designed Set |
/ |
Unkown |
| HY-100742AR |
(R)-GNE-140 (Standard) |
Inhibitor |
/ |
Unkown |
| HY-173452 |
DT-23 |
Inhibitor |
/ |
Unkown |
| HY-P6425S |
LCADMEDV-Arg(13C6,15N4) TFA |
|
/ |
Unkown |
| HY-RS17033 |
Arg1 Mouse Pre-designed siRNA Set A |
Pre-designed Set |
/ |
Unkown |
| HY-RS18727 |
Tinagl1 Mouse Pre-designed siRNA Set A |
Pre-designed Set |
/ |
Unkown |
| HY-RS23477 |
Arg1 Rat Pre-designed siRNA Set A |
Pre-designed Set |
/ |
Unkown |